New class of antimicrobials for treating mastitis in dairy animals
Our antimicrobial pipelines could be useful in preventing as well as treating mastitis in dairy animals. Animal husbandry is the backbone of farmers in developing countries, particularly in India, where majority of the small and marginal farmers lively hood depends on dairy farming. Mastitis is the inflammation of udder due to microbial pathogens colonization in mammary gland and the sole major cause of loss in milk production, as mastitis occurs at the peak of milk production, the mastitis milk is unfit for human consumption and export, causing severe loss (amounting to $ millions) to the farming community. A variety of microbes including bacteria, mycoplasma and yeast are involved in causing mastitis (example, but not limited to Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Brucella melitensis, Corynebacterium bovis, Mycoplasma sp., Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Pasteurella sp., Arcanobacterium pyogenes, Proteus sp., Prototheca sp., Cryptococcus neoformans and Candida albicans, Candida krusei, Candida parakrusei, Candida guilliermundi, and Candida tropicalis). Though the mastitis can be treated, however, the emergence of resistant bacteria is a menace to the farmer as well as doctors. This in turn lead to increased health care costs, loss of milk production, if ends in fibrosis of the udder then cow becomes unfit for milk production. Due to widespread prevalence of MDR and rapid appearance of resistance to newly introduced antimicrobials, further complicates treatment regiment and escalates treatment cost. Further, presence of multiple microbial infections (Gram positive, Gram negative bacteria, mycoplasma and yeast) worsens the situation, as none of the existing formulations could efficiently eliminate, as they are not effective against wide variety of microbes. Hence a novel formulation that could be used to address above problems is widely sought after. New class of antimicrobials developed and being evolved at Nanomicrobe are immune to bacterial resistance mechanism due to their unique mode of action.